Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Dendritic Cell Immunotherapy in DIPG
NCT02840123Phase 1Unknown
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Jun 2016
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in diffuse intrinsic pontine glioma (DIPG), sponsored by Fundació Sant Joan de Déu. Primary endpoint: Number of serious adverse events per patient at 2 years. Status: unknown.
02
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02840123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02840123.